ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer
Updated long-term follow-up data presented at ESMO 2025 reinforce the sustained benefit of adjuvant CDK4/6 inhibitors in patients with high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer.
